REDWOOD CITY, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 43^rd Annual Growth Conference in Boston. Management is scheduled to present on Wednesday, August 9, 2023, at 12:00 PM PT / 3:00 PM ET.

A live and archived webcast of the presentation will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr^® Endobronchial Valve, Chartis^® Pulmonary Assessment System and StratX^® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Pulmonx^®, Chartis^®, StratX^®, and Zephyr^® are registered trademarks of Pulmonx Corporation.

Contact
Brian Johnston
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.